These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34607745)

  • 21. Upfront cytoreductive surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer in Indian patients.
    Ray MD; Deo SSV; Kumar L; Gaur MK
    Future Oncol; 2021 Sep; 17(27):3607-3614. PubMed ID: 34263662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy in gynaecological cancers - Implications for staging.
    Kumar L; Pramanik R; Kumar S; Bhatla N; Malik S
    Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):790-801. PubMed ID: 25840650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
    Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
    [No Abstract]   [Full Text] [Related]  

  • 24. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of consolidation chemotherapy after delayed complete surgery in advanced epithelial ovarian cancer: a propensity score analysis.
    Godfroy M; Loaec C; Berton D; Guérin-Charbonnel C; Classe JM
    Int J Gynecol Cancer; 2023 Jan; 33(1):94-101. PubMed ID: 36517074
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
    Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
    J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Surgical therapy of ovarian cancer].
    Chovanec J; Feranec R; Náležinská M; Cacek T
    Rozhl Chir; 2017; 96(6):237-241. PubMed ID: 28931288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI
    Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of clinical effects of neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Jiang Y; He W; Yang H; Su Z; Sun L
    J BUON; 2018; 23(3):758-762. PubMed ID: 30003748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.
    Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY
    J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review.
    Xu T; Wang L; Jia Y; Jia Z; Li Z; Cui S; Cui M
    J Ovarian Res; 2019 Nov; 12(1):108. PubMed ID: 31711529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Searle G; Pounds R; Phillips A; Kehoe S; Balega J; Singh K; Yap J
    Gynecol Oncol; 2020 Jul; 158(1):54-58. PubMed ID: 32345546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
    Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
    J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
    Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
    Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.